Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of a cobalt(iii)-based ponatinib prodrug system.
Mathuber M, Gutmann M, La Franca M, Vician P, Laemmerer A, Moser P, Keppler BK, Berger W, Kowol CR. Mathuber M, et al. Inorg Chem Front. 2021 Mar 30;8(10):2468-2485. doi: 10.1039/d1qi00211b. Inorg Chem Front. 2021. PMID: 34046181 Free PMC article.
Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux.
Bormio Nunes JH, Hager S, Mathuber M, Pósa V, Roller A, Enyedy ÉA, Stefanelli A, Berger W, Keppler BK, Heffeter P, Kowol CR. Bormio Nunes JH, et al. Among authors: mathuber m. J Med Chem. 2020 Nov 25;63(22):13719-13732. doi: 10.1021/acs.jmedchem.0c01277. Epub 2020 Nov 15. J Med Chem. 2020. PMID: 33190481 Free PMC article.
Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.
Mathuber M, Schueffl H, Dömötör O, Karnthaler C, Enyedy ÉA, Heffeter P, Keppler BK, Kowol CR. Mathuber M, et al. Inorg Chem. 2020 Dec 7;59(23):17794-17810. doi: 10.1021/acs.inorgchem.0c03083. Epub 2020 Nov 21. Inorg Chem. 2020. PMID: 33222438 Free PMC article.
Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance.
Pósa V, Stefanelli A, Nunes JHB, Hager S, Mathuber M, May NV, Berger W, Keppler BK, Kowol CR, Enyedy ÉA, Heffeter P. Pósa V, et al. Among authors: mathuber m. Cancers (Basel). 2022 Sep 14;14(18):4455. doi: 10.3390/cancers14184455. Cancers (Basel). 2022. PMID: 36139615 Free PMC article.
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Caban M, Koblmueller B, Groza D, Schueffl HH, Terenzi A, Tolios A, Mohr T, Mathuber M, Kryeziu K, Jaunecker C, Pirker C, Keppler BK, Berger W, Kowol CR, Heffeter P. Caban M, et al. Among authors: mathuber m. Cancer Lett. 2023 Jul 1;565:216237. doi: 10.1016/j.canlet.2023.216237. Epub 2023 May 19. Cancer Lett. 2023. PMID: 37211067 Free article.
The anticancer thiosemicarbazone triapine exerts immune-enhancing activities via immunogenic cell death induction and FAS upregulation.
Stiller B, Stefanelli A, Schueffl H, Mathuber M, Skorokhyd N, Gufler J, Pirker C, Holcmann M, Panchuk R, Sibilia M, Marko D, Berger W, Kowol CR, Hager S, Heffeter P. Stiller B, et al. Among authors: mathuber m. Exp Hematol Oncol. 2025 Aug 22;14(1):109. doi: 10.1186/s40164-025-00700-0. Exp Hematol Oncol. 2025. PMID: 40847419 Free PMC article.